og with industry on the regulation of molecular tests while allowing them to operate as Laboratory Developed Tests (LDTs). • Starting an expedited Program for Serious Conditions (17 breakthrough therapy designations have been granted already). 19 OECD 2011 data 20 510(k) approval is the FDA section that allows for the appr